Orbimed Capital GP Viii LLC
SEC-identified person · CIK 1845804 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Sionna Therapeutics, Inc. SION | Director | filed 2025 - 2026 |
| Traws Pharma, Inc. TRAW | Officer | filed 2024 - 2026 |
| Gemini Therapeutics, Inc. /DE IRON | Director | filed 2023 - 2025 |
| Venetian-1 Acquisition Corp. | Director | filed 2024 - 2024 |
| Upstream Bio, Inc. UPB | Director | filed 2024 - 2024 |
| Kinnate Biopharma Inc. KNTE | Director | filed 2023 - 2024 |
| Arrivent Biopharma, Inc. AVBP | Director | filed 2024 - 2024 |
| Janux Therapeutics, Inc. JANX | Director | filed 2021 - 2021 |
| Decibel Therapeutics, Inc. [DBTX] | Director | filed 2021 - 2021 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.